- Belatacept prevents T-cell activation by blocking which of the following crucial signaling pathways?
Answer: Costimulatory signaling
Belatacept is a costimulation blocker. It is a fusion protein consisting of the extracellular domain of CTLA-4 linked to the Fc portion of IgG1. It binds with high affinity to CD80 (B7.1) and CD86 (B7.2) on antigen-presenting cells. This blocks these molecules from binding to their natural ligand, CD28, on T-cells. The CD28-B7 interaction provides a critical 'second signal' (costimulation) required for full T-cell activation. By blocking this signal, belatacept induces a state of T-cell anergy or apoptosis, preventing an effective immune response against the graft.
- The pathologic process in this patient's graft is primarily mediated by the activation of which of the following cells?
Answer: Recipient T-lymphocytes
The clinical presentation and histologic findings are classic for acute cellular rejection, the most common type of acute rejection. This process occurs weeks to months after transplantation and is a type IV hypersensitivity reaction. It is mediated by recipient CD8+ and CD4+ T-lymphocytes that recognize donor MHC molecules as foreign, leading to infiltration and destruction of the graft parenchyma.
- The T-cell response in this patient is most likely directed against which of the following targets?
Answer: Minor histocompatibility antigens
Even with a perfect match for the major histocompatibility complex (MHC, encoded by HLA genes), rejection can still occur due to differences in other proteins known as minor histocompatibility antigens. These are polymorphic, non-MHC proteins that are processed into peptides and presented by MHC molecules on donor cells. If the recipient's T-cell repertoire has not been tolerized to these specific peptides (e.g., proteins encoded on the Y chromosome in a male donor to a female recipient), they can be recognized as foreign and trigger a rejection response.
- A 60-year-old woman has slowly worsening cholestatic labs 5 years after liver transplant; biopsy shows fibrosis and narrowed bile ducts; she takes tacrolimus. Which of the following is the most likely cause of the observed symptoms?
Answer: Chronic rejection with progressive vascular and biliary injury
This question tests transplantation immunology concepts, focusing on rejection mechanisms and management (USMLE Step 1). Transplantation immunology involves understanding graft rejection types: hyperacute, acute, and chronic, each requiring different management. In this vignette, the patient's symptoms and lab results suggest chronic rejection, demonstrated by slowly worsening cholestatic labs and biopsy showing fibrosis. Choice A is correct because it reflects the vascular and biliary injury of chronic rejection based on current clinical guidelines. Choice C is incorrect due to acute rejection typically occurring early, not at 5 years. Teaching strategies include reviewing types of rejection and corresponding management protocols, emphasizing the importance of timely intervention and proper use of immunosuppressive therapy.
- This patient's condition is most likely caused by the activity of which of the following?
Answer: Donor T-cells recognizing recipient epithelial cells
This patient is presenting with classic signs of acute graft-versus-host disease (GVHD), a common complication of allogeneic stem cell transplantation. GVHD occurs when immunocompetent T-cells from the donor graft recognize the recipient's tissues as foreign and mount an inflammatory attack. The primary targets are the skin (rash), gastrointestinal tract (diarrhea), and liver (jaundice, elevated liver enzymes).
- What is the specific molecular target of basiliximab?
Answer: The α-chain (CD25) of the IL-2 receptor
Basiliximab is a monoclonal antibody that targets the alpha chain (CD25) of the IL-2 receptor. The CD25 subunit is highly expressed on activated T-lymphocytes. By blocking the IL-2 receptor, basiliximab prevents IL-2 from binding and signaling, which in turn inhibits the proliferation and activation of T-cells that are central to the acute rejection process. It is used as an induction agent to provide early, potent immunosuppression.
- The donor antigens that are recognized by the recipient's cytotoxic T-lymphocytes are primarily presented by which of the following molecules on the surface of donor kidney cells?
Answer: MHC class I
Acute cellular rejection is largely mediated by CD8+ cytotoxic T-lymphocytes (CTLs). These cells recognize foreign peptide antigens presented by MHC class I molecules. In the context of transplantation (direct allorecognition), the recipient's CD8+ T-cells directly recognize intact donor MHC class I molecules on the surface of graft cells as foreign. This interaction, along with costimulation, leads to the activation of CTLs, which then kill the graft cells via perforin/granzyme pathways. MHC class II molecules present antigens to CD4+ helper T-cells.
- Glucocorticoids are effective in treating acute rejection primarily through which of the following mechanisms?
Answer: Inhibiting transcription of inflammatory genes via NF-κB
Glucocorticoids exert broad anti-inflammatory and immunosuppressive effects. They bind to cytosolic receptors, and the resulting complex translocates to the nucleus where it alters gene expression. A key mechanism is the inhibition of transcription factors, such as nuclear factor-kappa B (NF-κB) and activator protein 1 (AP-1). This leads to decreased synthesis of numerous pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-6, TNF-α) and adhesion molecules, effectively suppressing the T-cell-mediated inflammatory response seen in acute rejection.
- A 50-year-old woman is 1 year after heart transplant with stable graft function; she takes tacrolimus and mycophenolate and has normal labs. What is the most appropriate next step in management?
Answer: Continue current immunosuppression with routine surveillance follow-up
This question tests transplantation immunology concepts, focusing on rejection mechanisms and management (USMLE Step 1). Transplantation immunology involves understanding graft rejection types: hyperacute, acute, and chronic, each requiring different management. In this vignette, the patient's symptoms and lab results suggest stable graft function, demonstrated by normal labs 1 year post-heart transplant. Choice A is correct because it reflects continuing immunosuppression with surveillance based on current clinical guidelines. Choice D is incorrect due to steroids not being indicated without rejection signs. Teaching strategies include reviewing types of rejection and corresponding management protocols, emphasizing the importance of timely intervention and proper use of immunosuppressive therapy.
- A 40-year-old man has rash and profuse diarrhea 3 weeks after allogeneic bone marrow transplant; labs show elevated bilirubin and low albumin; he takes tacrolimus and methotrexate. Which of the following mechanisms is most likely responsible for the patient's condition?
Answer: Donor CD4+ and CD8+ T cells recognizing recipient HLA antigens
This question tests transplantation immunology concepts, focusing on rejection mechanisms and management (USMLE Step 1). Transplantation immunology involves understanding graft rejection types: hyperacute, acute, and chronic, each requiring different management. In this vignette, the patient's symptoms and lab results suggest acute GVHD, demonstrated by rash, diarrhea, elevated bilirubin, and low albumin post-BMT. Choice A is correct because it reflects the donor T-cell mechanism in GVHD based on current clinical guidelines. Choice B is incorrect due to describing host T cells against graft, opposite of GVHD. Teaching strategies include reviewing types of rejection and corresponding management protocols, emphasizing the importance of timely intervention and proper use of immunosuppressive therapy.
- A 40-year-old man develops diffuse maculopapular rash and watery diarrhea 3 weeks after allogeneic bone marrow transplant; bilirubin is elevated and biopsy shows apoptotic bodies; he receives tacrolimus prophylaxis. What is the most likely cause of the observed symptoms?
Answer: Donor T lymphocytes attacking recipient skin, gut, and liver
This question tests transplantation immunology concepts, focusing on rejection mechanisms and management (USMLE Step 1). Transplantation immunology involves understanding graft rejection types: hyperacute, acute, and chronic, each requiring different management. In this vignette, the patient's symptoms and lab results suggest acute GVHD, demonstrated by rash, diarrhea, elevated bilirubin, and apoptotic bodies post-BMT. Choice A is correct because it reflects the donor T-cell attack in GVHD based on current clinical guidelines. Choice B is incorrect due to describing host antibodies against graft, not GVHD. Teaching strategies include reviewing types of rejection and corresponding management protocols, emphasizing the importance of timely intervention and proper use of immunosuppressive therapy. Distinguishing GVHD from host-versus-graft rejection is key in bone marrow transplant cases.
- What is the primary mechanism of action of sirolimus?
Answer: It inhibits a serine/threonine kinase involved in cell cycle progression.
Sirolimus (rapamycin) is an mTOR inhibitor. It binds to FKBP-12, but unlike tacrolimus, this complex does not inhibit calcineurin. Instead, the sirolimus-FKBP-12 complex binds to and inhibits the mammalian target of rapamycin (mTOR), a serine/threonine kinase. mTOR is critical for signaling downstream of the IL-2 receptor, and its inhibition blocks the progression of T-cells from the G1 to the S phase of the cell cycle, thereby preventing their proliferation.
- The rapid failure of this graft is most likely mediated by which of the following immunologic components?
Answer: Pre-formed recipient antibodies against donor antigens
This patient is experiencing hyperacute rejection, which occurs within minutes to hours after transplantation. It is a type II hypersensitivity reaction caused by pre-formed recipient antibodies (IgG or IgM) against donor ABO blood group or HLA antigens. These antibodies bind to the graft endothelium, activating complement and leading to widespread thrombosis, ischemia, and rapid graft failure.
- Matching which of the following sets of gene products is most critical for long-term graft survival?
Answer: Human leukocyte antigens (HLA)
The human leukocyte antigen (HLA) system, which encodes the major histocompatibility complex (MHC) proteins, is the most important factor in determining solid organ transplant compatibility. HLA molecules (Class I: HLA-A, B, C; Class II: HLA-DR, DQ, DP) present antigens to T-cells and are highly polymorphic. Mismatches in HLA, particularly HLA-A, HLA-B, and HLA-DR, are the primary drivers of T-cell-mediated rejection. While ABO matching is essential to prevent hyperacute rejection, long-term survival is most dependent on the degree of HLA matching.
- This process, where recipient APCs present processed donor antigens, is known as which of the following?
Answer: Indirect allorecognition
Indirect allorecognition occurs when recipient antigen-presenting cells (APCs) take up, process, and present peptides derived from donor MHC molecules (alloantigens) on their own MHC class II molecules. This activates recipient CD4+ T-cells, which then provide help to B-cells and macrophages, contributing to chronic inflammation, fibrosis, and the development of donor-specific antibodies. This pathway is a key driver of chronic rejection. In contrast, direct allorecognition involves recipient T-cells recognizing intact donor MHC molecules on donor APCs and is the dominant pathway in acute rejection.
- This patient's clinical and pathological findings are most consistent with which form of chronic lung allograft dysfunction?
Answer: Bronchiolitis obliterans syndrome
This patient's presentation is classic for bronchiolitis obliterans syndrome (BOS), the most common form of chronic lung allograft dysfunction (CLAD) and the leading cause of late mortality in lung transplant recipients. BOS is the pulmonary manifestation of chronic rejection, characterized pathologically by progressive inflammation and fibrosis of the small airways (bronchioles), leading to an irreversible obstructive ventilatory defect (decline in FEV1).
- Which of the following terms best describes the vascular pathology responsible for this patient's symptoms?
Answer: Graft vasculopathy
This patient's presentation is characteristic of chronic rejection of a cardiac allograft. The key pathological process is graft vasculopathy, also known as accelerated graft atherosclerosis. It is characterized by diffuse, concentric intimal thickening of graft arteries, leading to luminal stenosis, ischemia, and ultimately graft failure. This is a slow, progressive process mediated by both cellular and humoral immune responses.
- This acute hemolytic transfusion reaction is immunologically most analogous to which type of transplant rejection?
Answer: Hyperacute rejection
This patient is experiencing an acute hemolytic transfusion reaction, which is a type II hypersensitivity reaction. Individuals with type O blood have pre-formed IgM and IgG antibodies (anti-A and anti-B) in their plasma. When transfused with type A blood, these pre-formed antibodies bind to the A antigens on the donor red blood cells, leading to massive complement activation and intravascular hemolysis. This mechanism—pre-formed antibodies causing immediate destruction of foreign cells—is identical to that of hyperacute rejection of a solid organ transplant.
- A 35-year-old man has fever and rising creatinine 2 weeks after kidney transplant while on tacrolimus, mycophenolate, and prednisone; biopsy shows interstitial lymphocytes with tubulitis. Which of the following is the best initial treatment for this patient?
Answer: High-dose IV glucocorticoids to suppress T-cell activity
This question tests transplantation immunology concepts, focusing on rejection mechanisms and management (USMLE Step 1). Transplantation immunology involves understanding graft rejection types: hyperacute, acute, and chronic, each requiring different management. In this vignette, the patient's symptoms and lab results suggest acute cellular rejection, demonstrated by fever, rising creatinine, and biopsy showing lymphocytes with tubulitis. Choice A is correct because it reflects the appropriate initial treatment with high-dose steroids based on current clinical guidelines. Choice B is incorrect due to it being for antibody-mediated rejection, such as misinterpretation of biopsy as AMR. Teaching strategies include reviewing types of rejection and corresponding management protocols, emphasizing the importance of timely intervention and proper use of immunosuppressive therapy.
- A 35-year-old man has fever and graft tenderness 2 weeks after kidney transplant; creatinine is 3.0 mg/dL and Doppler is normal; he takes tacrolimus and mycophenolate. What is the most appropriate next step in management?
Answer: Obtain renal allograft biopsy to confirm rejection type
This question tests transplantation immunology concepts, focusing on rejection mechanisms and management (USMLE Step 1). Transplantation immunology involves understanding graft rejection types: hyperacute, acute, and chronic, each requiring different management. In this vignette, the patient's symptoms and lab results suggest acute rejection, demonstrated by fever, graft tenderness, and rising creatinine with normal Doppler. Choice C is correct because it reflects the appropriate next step of biopsy to confirm rejection type based on current clinical guidelines. Choice A is incorrect due to presuming infection without confirmation, such as misinterpretation of symptoms as solely infectious. Teaching strategies include reviewing types of rejection and corresponding management protocols, emphasizing the importance of timely intervention and proper use of immunosuppressive therapy.
